Spanish contract development and manufacturing organisation Bioingenium is investing €1.5m ($1.59m) in a Barcelona production plant to extend its line of active ingredients for the cosmetic industry.
The new centre in Cornellà de Llobregat, which will be fully operational in mid-2024, will have a surface area of 1,200 square metres.
Bioingenium said the plant will enhance its capacity for the development of bioprocesses and the manufacturing of therapeutic recombinant proteins and other biological products.
“The opening of this pilot plant will allow us to expand our production capacity and prepare for the next phase of the company's expansion in the cosmetics and food tech markets, as well as in other emerging and sustainable sectors,” added chief executive David Resina.
“The demand for biotechnology services is constantly increasing, and we believe that this new plant will give us a significant competitive advantage in these markets, in addition to facilitating a gradual increase in our production capacity to meet the current and future needs of the global market," he added.
Bioingenium has been manufacturing active ingredients for the cosmetics industry since 2017.
With a turnover of €1m, it experienced a 40% increase in its workforce in 2022, and a 30% increase in annual growth over the last three years.
Founded in 2008 in Barcelona Science Park, the company provides solutions to over 150 clients in 20 countries around the world.
